Breast cancer in men. Clinical features, hormone receptor status, and response to therapy

W. R. Bezwoda, C. Hesdorffer, R. Dansey, N. De Moor, D. P. Derman, S. Browde, M. Lange

Research output: Contribution to journalArticle

Abstract

Stage, estrogen receptor status, treatment and survival of 29 men with breast cancer attending the Breast Clinic of the Johannesburg Hospital between 1976 and 1985 are reviewed. Most patients had locoregionally advanced disease at presentation. Estrogen receptors (ER) were detected in significant concentration in 15/23 (65%). Local control was achieved in the majority, 19/26 (73%), by either surgery or radiation therapy alone or by combined modality treatment. Fifteen of 23 patients tested (65%) were ER-positive (>10 fmol/mg protein). For patients with metastatic disease hormone receptor status was predictive of response to hormonal manipulation. Tamoxifen was the most acceptable and frequently used form of hormone therapy with 7/12 patients responding. Combination chemotherapy gave a response rate comparable to that seen in women with breast cancer.

Original languageEnglish (US)
Pages (from-to)1337-1340
Number of pages4
JournalCancer
Volume60
Issue number6
StatePublished - 1987
Externally publishedYes

Fingerprint

Estrogen Receptors
Hormones
Breast Neoplasms
Tamoxifen
Therapeutics
Combination Drug Therapy
Radiotherapy
Survival
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bezwoda, W. R., Hesdorffer, C., Dansey, R., De Moor, N., Derman, D. P., Browde, S., & Lange, M. (1987). Breast cancer in men. Clinical features, hormone receptor status, and response to therapy. Cancer, 60(6), 1337-1340.

Breast cancer in men. Clinical features, hormone receptor status, and response to therapy. / Bezwoda, W. R.; Hesdorffer, C.; Dansey, R.; De Moor, N.; Derman, D. P.; Browde, S.; Lange, M.

In: Cancer, Vol. 60, No. 6, 1987, p. 1337-1340.

Research output: Contribution to journalArticle

Bezwoda, WR, Hesdorffer, C, Dansey, R, De Moor, N, Derman, DP, Browde, S & Lange, M 1987, 'Breast cancer in men. Clinical features, hormone receptor status, and response to therapy', Cancer, vol. 60, no. 6, pp. 1337-1340.
Bezwoda WR, Hesdorffer C, Dansey R, De Moor N, Derman DP, Browde S et al. Breast cancer in men. Clinical features, hormone receptor status, and response to therapy. Cancer. 1987;60(6):1337-1340.
Bezwoda, W. R. ; Hesdorffer, C. ; Dansey, R. ; De Moor, N. ; Derman, D. P. ; Browde, S. ; Lange, M. / Breast cancer in men. Clinical features, hormone receptor status, and response to therapy. In: Cancer. 1987 ; Vol. 60, No. 6. pp. 1337-1340.
@article{5613a91344af4c549ff1e6b5f300d2d3,
title = "Breast cancer in men. Clinical features, hormone receptor status, and response to therapy",
abstract = "Stage, estrogen receptor status, treatment and survival of 29 men with breast cancer attending the Breast Clinic of the Johannesburg Hospital between 1976 and 1985 are reviewed. Most patients had locoregionally advanced disease at presentation. Estrogen receptors (ER) were detected in significant concentration in 15/23 (65{\%}). Local control was achieved in the majority, 19/26 (73{\%}), by either surgery or radiation therapy alone or by combined modality treatment. Fifteen of 23 patients tested (65{\%}) were ER-positive (>10 fmol/mg protein). For patients with metastatic disease hormone receptor status was predictive of response to hormonal manipulation. Tamoxifen was the most acceptable and frequently used form of hormone therapy with 7/12 patients responding. Combination chemotherapy gave a response rate comparable to that seen in women with breast cancer.",
author = "Bezwoda, {W. R.} and C. Hesdorffer and R. Dansey and {De Moor}, N. and Derman, {D. P.} and S. Browde and M. Lange",
year = "1987",
language = "English (US)",
volume = "60",
pages = "1337--1340",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Breast cancer in men. Clinical features, hormone receptor status, and response to therapy

AU - Bezwoda, W. R.

AU - Hesdorffer, C.

AU - Dansey, R.

AU - De Moor, N.

AU - Derman, D. P.

AU - Browde, S.

AU - Lange, M.

PY - 1987

Y1 - 1987

N2 - Stage, estrogen receptor status, treatment and survival of 29 men with breast cancer attending the Breast Clinic of the Johannesburg Hospital between 1976 and 1985 are reviewed. Most patients had locoregionally advanced disease at presentation. Estrogen receptors (ER) were detected in significant concentration in 15/23 (65%). Local control was achieved in the majority, 19/26 (73%), by either surgery or radiation therapy alone or by combined modality treatment. Fifteen of 23 patients tested (65%) were ER-positive (>10 fmol/mg protein). For patients with metastatic disease hormone receptor status was predictive of response to hormonal manipulation. Tamoxifen was the most acceptable and frequently used form of hormone therapy with 7/12 patients responding. Combination chemotherapy gave a response rate comparable to that seen in women with breast cancer.

AB - Stage, estrogen receptor status, treatment and survival of 29 men with breast cancer attending the Breast Clinic of the Johannesburg Hospital between 1976 and 1985 are reviewed. Most patients had locoregionally advanced disease at presentation. Estrogen receptors (ER) were detected in significant concentration in 15/23 (65%). Local control was achieved in the majority, 19/26 (73%), by either surgery or radiation therapy alone or by combined modality treatment. Fifteen of 23 patients tested (65%) were ER-positive (>10 fmol/mg protein). For patients with metastatic disease hormone receptor status was predictive of response to hormonal manipulation. Tamoxifen was the most acceptable and frequently used form of hormone therapy with 7/12 patients responding. Combination chemotherapy gave a response rate comparable to that seen in women with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023615565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023615565&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 1337

EP - 1340

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -